271 related articles for article (PubMed ID: 35867773)
1. Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model.
Ruiz-Martinez A; Gong C; Wang H; Sové RJ; Mi H; Kimko H; Popel AS
PLoS Comput Biol; 2022 Jul; 18(7):e1010254. PubMed ID: 35867773
[TBL] [Abstract][Full Text] [Related]
2. A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy.
Gong C; Ruiz-Martinez A; Kimko H; Popel AS
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359653
[TBL] [Abstract][Full Text] [Related]
3. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
[TBL] [Abstract][Full Text] [Related]
4. From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy.
Lemaire V; Bassen D; Reed M; Song R; Khalili S; Lien YTK; Huang L; Singh AP; Stamatelos S; Bottino D; Hua F
Clin Pharmacol Ther; 2023 May; 113(5):963-972. PubMed ID: 36282521
[TBL] [Abstract][Full Text] [Related]
5. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
6. Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response.
Zhang S; Gong C; Ruiz-Martinez A; Wang H; Davis-Marcisak E; Deshpande A; Popel AS; Fertig EJ
Immunoinformatics (Amst); 2021 Oct; 1-2():. PubMed ID: 34708216
[TBL] [Abstract][Full Text] [Related]
7. Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment.
Norton KA; Gong C; Jamalian S; Popel AS
Processes (Basel); 2019 Jan; 7(1):. PubMed ID: 30701168
[TBL] [Abstract][Full Text] [Related]
8. Recent applications of quantitative systems pharmacology and machine learning models across diseases.
Aghamiri SS; Amin R; Helikar T
J Pharmacokinet Pharmacodyn; 2022 Feb; 49(1):19-37. PubMed ID: 34671863
[TBL] [Abstract][Full Text] [Related]
9. Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.
Cheng L; Qiu Y; Schmidt BJ; Wei GW
J Pharmacokinet Pharmacodyn; 2022 Feb; 49(1):39-50. PubMed ID: 34637069
[TBL] [Abstract][Full Text] [Related]
10. Quantifying Intratumoral Heterogeneity and Immunoarchitecture Generated In-Silico by a Spatial Quantitative Systems Pharmacology Model.
Nikfar M; Mi H; Gong C; Kimko H; Popel AS
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345087
[TBL] [Abstract][Full Text] [Related]
11. Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology.
Arulraj T; Wang H; Ippolito A; Zhang S; Fertig EJ; Popel AS
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38557676
[TBL] [Abstract][Full Text] [Related]
12. Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors.
Wang H; Sové RJ; Jafarnejad M; Rahmeh S; Jaffee EM; Stearns V; Roussos Torres ET; Connolly RM; Popel AS
Front Bioeng Biotechnol; 2020; 8():141. PubMed ID: 32158754
[TBL] [Abstract][Full Text] [Related]
13. Virtual Populations for Quantitative Systems Pharmacology Models.
Cheng Y; Straube R; Alnaif AE; Huang L; Leil TA; Schmidt BJ
Methods Mol Biol; 2022; 2486():129-179. PubMed ID: 35437722
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer.
Wang H; Zhao C; Santa-Maria CA; Emens LA; Popel AS
iScience; 2022 Aug; 25(8):104702. PubMed ID: 35856032
[TBL] [Abstract][Full Text] [Related]
15. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Fleisher B; Brown AN; Ait-Oudhia S
Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
17. Dynamical systems analysis as an additional tool to inform treatment outcomes: The case study of a quantitative systems pharmacology model of immuno-oncology.
Balti A; Zugaj D; Fenneteau F; Tremblay PO; Nekka F
Chaos; 2021 Feb; 31(2):023124. PubMed ID: 33653032
[TBL] [Abstract][Full Text] [Related]
18. Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices.
Bai JPF; Earp JC; Pillai VC
AAPS J; 2019 Jun; 21(4):72. PubMed ID: 31161268
[TBL] [Abstract][Full Text] [Related]
19. A QSP model of prostate cancer immunotherapy to identify effective combination therapies.
Coletti R; Leonardelli L; Parolo S; Marchetti L
Sci Rep; 2020 Jun; 10(1):9063. PubMed ID: 32493951
[TBL] [Abstract][Full Text] [Related]
20. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
Qi T; Liao X; Cao Y
Trends Pharmacol Sci; 2023 Dec; 44(12):880-890. PubMed ID: 37852906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
